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Purpose of the study
The prevalence of osteoporosis in a HIV-positive cohort is
more than three times higher than in matched HIV-nega-
tive controls. While ART treatment has been associated
with increased odds of reduced bone density compared
with ART-naive patients, the pathogenic mechanisms
underlying the initiation and progression of osteoporosis
in HIV patients remain to be elucidated. Recent studies
have reported altered bone biology and function in
response to ART exposure, including effects on osteoclasts
and osteoblasts. However, the direct effect of HIV on bone
cell biology has not been evaluated. We hypothesized that
exposure to HIV alters human osteoblast function and
activity and ultimately leads to osteopenia/osteoporosis.
Methods
Primary human osteoblasts (hOB) were cultured in
growth medium in vitro. Growth medium was supple-
mented with serum from three distinct patient groups
(HIV-negative, HIV-positive low [VL range 120; 4000] or
high [VL range 100,000; 500,000]) viral load serum (5%
conc., 72 hours, n = 5 per patient group, HIV serum
obtained from ART-naïve patients). Cell proliferation (as
a biological end-point) and calcium deposition (as a func-
tional end-point) were determined using established
methods. In addition, to identify the effect of HIV on tran-
scriptional regulators of the bone phenotype, real-time
PCR with gene-specific primers was used to quantify
mRNA expression of RUNX-2, a pro-osteogenic transcrip-
tion factor.
Summary of results
Exposure of hOB to control, low or high HIV viral load
serum did not affect hOB cell proliferation, demonstrat-
ing that these exposures did not have a cytotoxic effect on
osteoblasts in vitro. HOB calcium deposition reduced sig-
nificantly (p < 0.005) after treatment with high VL serum
compared to either low VL or HIV-negative control serum.
Osteoblast RUNX-2 mRNA expression declined by 25%
(p < 0.05) after exposure to high VL serum compared to
HIV-negative controls.
Conclusion
These data demonstrate bioactivity of HIV in the setting of
osteoblast cell culture. Serum obtained from HIV patients
with high VL effected significant changes in the bone phe-
notype, as evidenced by reduced capacity for calcium dep-
osition. Intriguingly, this functional effect was mirrored
by changes in the expression of the osteogenic transcrip-
tion factor RUNX-2. These findings support the hypothe-
sis that HIV itself, in addition to the well described effect
of ART, can modulate bone phenotype and at least in part,
drive the osteopenia and osteoporosis which is increas-
ingly seen in HIV patients.
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